Researchers at the University of Pittsburgh, UPMC Hillman Cancer Center, and the National Cancer Institute have demonstrated that combining CAR T cell immunotherapy with the radiopharmaceutical [67Cu]Cu-LLP2A significantly improves tumor regression in preclinical neuroblastoma models. By pairing cellular therapy with targeted radiation, the study achieved an 80% increase in complete response rates compared to using the radioactive drug alone, according to findings published in Cell Reports Medicine.
How does the combination therapy target solid tumors?
The primary hurdle for CAR T cell therapy in solid tumors is the tumor microenvironment—a dense, suppressive network of cells and signaling molecules that physically blocks engineered T cells from reaching their target. According to the research team, [67Cu]Cu-LLP2A acts as a precision tool to breach these defenses. Unlike external beam radiation, which is limited to a fixed site, this radioactive drug circulates through the bloodstream to locate tumors wherever they have metastasized.
The drug targets the VLA-4 receptor, which is expressed on both tumor cells and surrounding immune cells. By delivering radiation directly to these sites, the drug effectively primes the tumor for an immune attack, allowing CAR T cells to penetrate previously inaccessible areas.
CAR T cell therapy involves collecting a patient’s own T cells, genetically engineering them to identify specific cancer markers, and reintroducing them into the body. While highly successful in treating certain blood cancers, this approach has historically struggled to gain a foothold against solid tumors like neuroblastoma.
What are the two mechanisms of tumor regression?
The effectiveness of the combination therapy depends on the tumor’s specific biological makeup. Senior author Ravi Patel, M.D., Ph.D., director of radiopharmaceutical therapy in the Department of Radiation Oncology at UPMC Hillman Cancer Center, notes that the treatment creates two distinct pathways for success:
- Radiation-sensitive tumors: The drug damages cancer cells directly, triggering an inflammatory response that acts as a signal to attract and activate CAR T cells.
- Radiation-resistant tumors: In these more difficult cases, the drug does not kill the cancer cells immediately. Instead, it remodels the tumor microenvironment by reducing suppressive immune cells, effectively turning a “cold” tumor into an environment where CAR T cells can successfully infiltrate and function.
What are the next steps for clinical application?
While the results in preclinical models show significant promise, the treatment is not yet available for human patients. Before clinical trials can commence, researchers must establish safety and toxicity profiles to ensure the combination is well-tolerated. According to the study, the team is currently focusing on three critical areas to advance this approach:
- Biomarker identification: Determining which patients are most likely to respond to this specific combination of therapies.
- Imaging-guided dosing: Using advanced imaging techniques to deliver precise, effective doses of the radiopharmaceutical.
- Safety validation: Establishing safe dosing and toxicity profiles.
For families dealing with high-risk neuroblastoma, staying informed about the transition from preclinical research to human trials is vital. You can monitor the National Cancer Institute for updates on emerging immunotherapies and clinical trial opportunities.
Frequently Asked Questions
Why has CAR T therapy historically failed in solid tumors?
In blood cancers, malignant cells float freely in the bloodstream, making them easy targets for T cells. In solid tumors, the surrounding tissue creates a physical and chemical barrier that prevents engineered T cells from entering or surviving long enough to attack the cancer.
How much did the combination improve outcomes in the study?
The study found that adding CAR T cell therapy to radiopharmaceutical treatment increased tumor shrinkage and complete response rates by 80% compared to using the radioactive drug alone in the preclinical models.
When will this treatment be available for patients?
The research is currently in the preclinical stage. Additional studies are required to define safe dosing and identify patient-specific biomarkers before the approach can be tested in human clinical trials.
Have questions about the latest advancements in pediatric cancer research? Subscribe to our newsletter for updates on breakthroughs in immunotherapy and clinical oncology.
